Target intelligence / Profile preview

DNA-dependent metalloprotease SPRTN (SPRTN)

Target
SPRTN
Molecular classification
Enzyme, Metalloprotease, DNA repair protein, Contains SprT-like domain
01

Overview

SPRTN is a specialized, DNA-dependent metalloprotease critical for maintaining genome integrity by cleaving DNA-protein crosslinks (DPCs) that would otherwise hinder DNA replication[1][2]. SPRTN activity is tightly regulated: it is recruited to stalled replication forks via PCNA-interacting and ubiquitin-binding domains, is activated by specific DNA structures, and is controlled by posttranslational modifications such as ubiquitination to prevent inappropriate proteolysis[1][2][4]. Its proteolytic activity is restricted to DNA-bound substrates during S phase, thereby resolving cytotoxic lesions and preventing replication stress[1]. Dysfunction or mutations in SPRTN are implicated in Ruijs–Aalfs syndrome, a progeroid disorder characterized by genomic instability, premature aging, and a predisposition to cancers, especially hepatocellular carcinoma[1][3][5]. SPRTN also coordinates DNA damage tolerance pathways, influencing the switch between replicative and translesion synthesis DNA polymerases and broader aspects of DNA repair and genome maintenance[1][2].

Other names
DVC1SpartanC1orf124PRO4323DNA damage protein targeting VCPDNA damage-targeting VCP (p97) adaptorzinc finger RAD18 domain-containing proteinSprT-like N-terminal domain
02

Biological functions

DNA-protein crosslink (DPC) repairGenome integrity maintenanceDNA replication stress responseRegulation of translesion synthesis (TLS)Modulation of DNA damage tolerance pathwaysRegulation of replication fork progression
03

Disease associations

CancerPremature aging syndromes (e.g. Ruijs–Aalfs syndrome)Genomic instability disordersHepatocellular carcinoma
04

Safety considerations

Genomic instability from SPRTN dysfunctionRisk of premature agingCancer predisposition when defective or dysregulated
05

Biomarkers

SPRTN mutations for Ruijs–Aalfs syndrome diagnosisPotential susceptibility biomarker for cancer and genomic instability

Beyond the preview

Go deeper on DNA-dependent metalloprotease SPRTN (SPRTN).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on DNA-dependent metalloprotease SPRTN (SPRTN).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call